Show simple item record

dc.contributor.authorEarl, H
dc.contributor.authorVallier, A
dc.contributor.authorDunn, J
dc.contributor.authorLoi, S
dc.contributor.authorOgburn, E
dc.contributor.authorMcAdam, K
dc.contributor.authorHughes-Davies, L
dc.contributor.authorHarnett, A
dc.contributor.authorAbraham, J
dc.contributor.authorWardley, Andrew M
dc.contributor.authorCameron, D
dc.contributor.authorMiles, D
dc.contributor.authorGounaris, I
dc.contributor.authorPlummer, C
dc.contributor.authorHiller, L
dc.date.accessioned2017-01-18T10:22:35Z
dc.date.available2017-01-18T10:22:35Z
dc.date.issued2016-12-06
dc.identifier.citationTrastuzumab-associated cardiac events in the Persephone trial. 2016, 115 (12):1462-1470 Br. J. Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid27875516
dc.identifier.doi10.1038/bjc.2016.357
dc.identifier.urihttp://hdl.handle.net/10541/620082
dc.description.abstractWe report cardiac events in the Persephone trial which compares 6-12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titleTrastuzumab-associated cardiac events in the Persephone trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, University of Cambridge, (Box 193-R4) Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractWe report cardiac events in the Persephone trial which compares 6-12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer.


This item appears in the following Collection(s)

Show simple item record